BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29369199)

  • 1. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
    Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
    Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
    Cetin S; Dede I
    J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma.
    Liu F; Hu HJ; Ma WJ; Yang Q; Wang JK; Li FY
    Medicine (Baltimore); 2019 Feb; 98(8):e14550. PubMed ID: 30813165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.
    Kim WJ; Lim TW; Park PJ; Choi SB; Kim WB
    ANZ J Surg; 2019 Jul; 89(7-8):E302-E307. PubMed ID: 30895709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
    Guo J; Wu M; Guo L; Zuo Q
    Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
    Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
    Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.
    Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA
    J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
    Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
    Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
    Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
    World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
    Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
    Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 14. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
    Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
    J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
    Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
    Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
    Murali Manohar K; Sasikala M; Kvsrr Y; Sunil V; Talukdar R; Murthy H; Ramji C; Rao GV; Pradeep R; Reddy DN
    Tumour Biol; 2017 Mar; 39(3):1010428317695018. PubMed ID: 28351309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
    Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
    J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
    Zhang Y; Jiang C; Li J; Sun J; Qu X
    Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
    Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.